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Abdominal aortic surgery in patients with human immunodeficiency
virus infection
Lin PH, Bush RL, Yao Q, et al. Am J Surg 2004;188:690-97.
Conclusion: Perioperative mortality and morbidity is high in HIV
patients undergoing abdominal aortic surgery. Hypoalbuminemia and low
CD4 lymphocyte counts are associated with poor clinical outcomes.
Summary: The authors assessed outcome in HIV patients undergoing
aortic reconstruction for occlusive or aneurysmal disease. This retrospective
study covered an 11-year period, with patients identified through hospital
and clinic records. The authors identified 48 HIV-positive patients (mean
age 53  13 years) who underwent an abdominal aortic procedure during
the study period. There were 20 operations for aneurysm and 28 for
occlusive disease. There were no intraoperative deaths. Sixteen patients
(33%) had postoperative complications, and 7 patients (15%) died in the
hospital. Follow-upwas for amean of 41months. Survival rates for aneurysm
patients at 60 months were 43.2% 5.3% and for occlusive disease patients,
46.3% 7.4% (PNS). Multivariable analysis indicated low CD4 lympho-
cyte counts (200/L, P 0.05) and hypoalbuminemia (3.5g/dL, P
0.05) were risk factors for perioperative complication. The incidence of late
graft infection was 10%. All patients with graft infection died, either from
complications of the graft infection or its treatment.
Comment: Everyone likes to publish good results. It is, however,
sometimes the responsible thing to publish horrible results. Clearly the
results of aortic surgery in patients with HIV infection are significantly
inferior to what one would expect in patients without HIV infection. The
message: aortic reconstruction in patients with HIV infection should be
undertaken only for compelling indications.
Coronary-artery revascularization before elective major vascular surgery
McFalls EO, Ward HB, Moritz TE, et al. N Engl J Med 2004;351:2795-
804.
Conclusions: Long-term outcome in patients with stable cardiac
symptoms is not altered by coronary artery revascularization before elective
vascular surgery.
Summary: The authors sought to assess the long-term benefit of
coronary artery revascularization in patients with stable coronary artery
disease who are scheduled for elective vascular surgery. Patients considered
at increased risk for perioperative cardiac complications and who had clini-
cally significant coronary artery disease were randomly assigned to undergo
either coronary revascularization or no coronary artery revascularization
before elective major vascular surgery. The primary end point was long-term
mortality. There were 5,859 patients scheduled for vascular operations at 18
Department of Veteran’s Affairs Medical Centers who were eligible for the
study. Of these, 510 (9%) were randomly assigned to either coronary artery
revascularization before surgery, or no coronary artery revascularization
before surgery.
The indication for vascular surgery was arterial occlusive disease of the
legs in 67% of the patients and repair of an abdominal aortic aneurysm in
33%. In the patients assigned to preoperative coronary artery revasculariza-
tion, bypass graft surgery was performed in 41% and percutaneous coronary
artery interventions in 59%. Median time from randomization to vascular
surgery was 54 days in the coronary artery revascularization cohort, and 18
days in the patients not undergoing revascularization (P  .001). At 2.7
years after randomization, the mortality rates were 22% in the revasculariza-
tion group and 23% in the no-revascularization group (relative risk 0.98;
95% confidence interval, 0.70 to 1.37; P  .92). Postoperative myocardial
infarctions, as defined by troponin levels, occurred 30 days after the
vascular surgical procedure in 12% of the revascularization group and in 14%
of the no-revascularization group (P  .37).
Comment: This study, like all studies, must be interpreted with respect
to the patients studied and the study conditions. Patients were carefully
screened for unstable cardiac disease. Such patients were excluded. In
addition, approximately 85% of the patients in the coronary and no coronary
revascularization group were treated with perioperative -blockers, and 77%
of the patients in the revascularization group and 70% in the no revascular-
ization group treated with aspirin. The overall results therefore indicate that
patients treated with aggressive medical management and who are carefully
screened for unstable coronary disease will not benefit from coronary revas-
cularization before major vascular surgery. In patients with stable cardiac
symptoms, a strategy of coronary-artery revascularization cannot be recom-
mended before elective vascular surgery.
C-reactive protein levels and outcomes after statin therapy
Ridker PM, Cannon CP, Morrow D, et al. N Engl J Med 2005;352:20-8.
Conclusion: Low C-reactive protein (CRP) levels after statin therapy
predict better a clinical outcome than higher CRP levels, regardless of
low-density-lipoprotein (LDL) cholesterol levels. CRP and cholesterol lev-
els should both be monitored with statin therapy.
Summary: The authors investigated 3,745 patients with acute coro-
nary syndromes. The relation between CRP levels and LDL cholesterol
achieved after treatment with 40 mg of pravastatin or 80 mg of atorvastatin
was evaluated in terms of risk of recurrent myocardial infarction or death
from a coronary cause.
When statin therapy resulted in LDL cholesterol levels 70 mg/dL,
the patients had lower event rates than those with higher LDL levels (2.7 vs
4.0 events/100 person-years, P  .008). Patients with CRP levels of 2
mg/L after statin therapy had lower events rates than patients with higher
CRP levels (2.8 vs 3.9 events/100 person-years, P  .006). This effect was
present at all levels of LDL cholesterol achieved after statin therapy.
In patients with LDL cholesterol levels 70 mg/dL after treatment,
rates of recurrent events were 4.6/100 person-years when the CRP level was
2 mg/L and 3.2/100 person-years when CRP levels were 2 mg/L.
Event rates among those patients with LDL cholesterol levels 70 mg/dL
were 3.1 and 2.4/100 person-years (P 0.001) for CRP levels2mg/L or
2 mg/L, respectively. Overall, atorvastatin was more likely than pravasta-
tin to result in lower levels of LDL cholesterol and CRP. The lowest rate of
recurrent events (1.9/100 person-years) occurred in those patients who had
LDL cholesterol levels 70 g/dL and CRP levels 1 mg/L after statin
therapy.
Comment: The data imply that therapies designed to reduce both
inflammation and cholesterol levels may improve outcomes in patients with
atherosclerotic disease. The current data obviously directly apply only to
patients who have had acute coronary syndromes. Nevertheless, this is
another suggestion that patients with diffuse atherosclerosis will benefit not
only from cholesterol lowering but also from control of inflammation.
Local versus general anesthetic for carotid endarterectomy
Rerkasem K, Bond R, Rothwell PM. Stroke 2005; 36:169-70.
Conclusion:There is insufficient evidence to allow reliable conclusions
to be drawn regarding the efficacy of local versus general anesthesia for
carotid endarterectomy.
Summary: This is a Cochrane review designed to assess the risk of
carotid endarterectomy performed under general versus local anesthesia.
Two reviewers independently reviewedMEDLINE, EMBASE, and Index to
Scientific and Technical Proceedings. Relevant journals were also hand
searched and references identified. For inclusion in the review, trials must
have been randomized trials or nonrandomized trials that compared carotid
endarterectomy under general versus local anesthesia.
The authors identified 41 nonrandomized trials involving 25,622
operations and 7 randomized trials involving 5,554 operations. The meth-
odologic quality of many of the nonrandomized trials was considered
questionable. Data analysis of the nonrandomized trials showed reductions
in odds of death, stroke, stroke or death, myocardial infarction, and pulmo-
nary complications with use of local anesthesia. Analysis of the seven ran-
domized studies revealed nonsignificant trends towards reduced mortality
with local anesthesia (pooled odds ratio 0.23; 95% confidence interval, 0.05
to 1.02). The result, however, was based on a total number of strokes and
deaths of 7 in the local anesthesia group versus 11 in the general anesthetic
group.
Comment: Nonrandomized trials have an obvious potential for bias.
Overall, one must agree with the Cochrane reviewers. Currently, no scien-
tifically valid evidence supports one form of anesthesia over another in the
performance of carotid endarterectomy.
JOURNAL OF VASCULAR SURGERY
Volume 41, Number 4 Abstracts 733
